drugset / Trial / NCT00834574
Cefdinir for Oral Suspension 250 mg/5mL, Fasting
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects under fasting conditions.
Timeline
- Start
- 2005-02
- Primary completion
- 2005-03
- Completion
- 2005-03
Outcome
Met primary endpoint
registry analysis (unspecified test); Cefdinir (Test) vs Omnicef® (Reference); Ratio of the T/R geometric mean x 100 103 (90% CI 97.2 to 110) NCT00834574 ↗
registry analysis (unspecified test); Cefdinir (Test) vs Omnicef® (Reference); Ratio of the T/R geometric mean x 100 107 (90% CI 101 to 114) NCT00834574 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cefdinir | Other / unclassified | 250 mg | Oral |
Indications
No indication recorded.